{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:20:17Z","timestamp":1794561617414,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.urolonc.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T08:26:27Z","timestamp":1519979187000},"page":"240.e1-240.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Association among metabolic syndrome, inflammation, and survival in prostate cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Maines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Kinspergher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Fratino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore Luca","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.01.007_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clgc.2013.04.009","article-title":"Metabolic syndrome as a peculiar target for management of prostate cancer patients","volume":"11","author":"Conteduca","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pros.23014","article-title":"Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone","volume":"75","author":"Conteduca","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2018.01.007_bib3","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.juro.2012.11.017","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"189","author":"Saylor","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urolonc.2018.01.007_bib5","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2018.01.007_bib6","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2012.09.008","article-title":"The possible cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy","volume":"86","author":"Conteduca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.urolonc.2018.01.007_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/annonc\/mdq443","article-title":"Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer","volume":"22","author":"Flanagan","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/er.2002-0010","article-title":"Insulin resistance and chronic cardiovascular inflammatory syndrome","volume":"24","author":"Fernandez-Real","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.urolonc.2018.01.007_bib11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib12","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","article-title":"Obesity and cancer mechanisms: tumor microenvironment and inflammation","volume":"34","author":"Iyengar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib13","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2018.01.007_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","article-title":"Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"25","author":"Leibowitz-Amit","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fphar.2016.00376","article-title":"Systemic Immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone","volume":"7","author":"Lolli","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib16","doi-asserted-by":"crossref","first-page":"e0158952","DOI":"10.1371\/journal.pone.0158952","article-title":"Persistent neutrophil to lymphocyte ratio>3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer","volume":"11","author":"Conteduca","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2018.01.007_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.urolonc.2018.01.007_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2018.01.007_bib19","first-page":"312re10","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"312","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2018.01.007_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/bjc.2015.128","article-title":"Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone","volume":"112","author":"Salvi","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib21","doi-asserted-by":"crossref","first-page":"37839","DOI":"10.18632\/oncotarget.9341","article-title":"Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration resistant prostate cancer","volume":"7","author":"Salvi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2018.01.007_bib22","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/bju.13428","article-title":"Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence","volume":"118","author":"Rudman","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.01.007_bib26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.22534","article-title":"Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men","volume":"109","author":"Gong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S1470-2045(08)70235-3","article-title":"Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis","volume":"9","author":"Ma","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1158\/1940-6207.CAPR-10-0229","article-title":"Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis","volume":"4","author":"Cao","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.urolonc.2018.01.007_bib29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.22932","article-title":"Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer","volume":"110","author":"Halabi","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","article-title":"The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation","volume":"60","author":"De Nunzio","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature08782","article-title":"B-cell-derived lymphotoxin promotes castration-resistant prostate cancer","volume":"464","author":"Ammirante","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.01.007_bib32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.22788","article-title":"Elevated IL-8, TNF-\u03b1, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival","volume":"74","author":"Sharma","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2018.01.007_bib33","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2217\/fon.15.158","article-title":"Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients","volume":"11","author":"Conteduca","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/pcan.2017.1","article-title":"Meta-analysis of metabolic syndrome and prostate cancer","volume":"20","author":"Gacci","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2018.01.007_bib35","doi-asserted-by":"crossref","first-page":"e0153981","DOI":"10.1371\/journal.pone.0153981","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Tang","year":"2016","journal-title":"Plos one"},{"key":"10.1016\/j.urolonc.2018.01.007_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2013.09.005","article-title":"Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy","volume":"65","author":"Mulders","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib37","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(14)70417-6","article-title":"Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial","volume":"15","author":"Sternberg","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2014.05.008","article-title":"Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies","volume":"92","author":"Conteduca","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2018.01.007_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/2159-8290.CD-11-0259","article-title":"Understanding the lethal variant of prostate cancer: power of examining extremes!","volume":"1","author":"Aparicio","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2018.01.007_bib40","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.2337\/db13-1505","article-title":"Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome","volume":"63","author":"Yu","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.urolonc.2018.01.007_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/ERC-14-0107","article-title":"Upregulation of glucose metabolism by NF-\u03baB2\/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells","volume":"21","author":"Cui","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1677\/ERC-08-0174","article-title":"Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor","volume":"16","author":"Malinowska","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2018.01.007_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/pcan.2016.25","article-title":"A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients","volume":"19","author":"Kiwata","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2018.01.007_bib44","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","article-title":"A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy","volume":"109","author":"Nobes","year":"2012","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:12:05Z","timestamp":1761041525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1078143918300073"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association among metabolic syndrome, inflammation, and survival in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}